I. The Central Question

A primary neurological or systemic vascular condition may have been present since early adulthood or before, expressing itself across multiple systems simultaneously. The current diagnostic picture (seropositive RA, fibromyalgia, cryptogenic strokes, intracranial aneurysms) may represent downstream expressions of this upstream condition rather than independent co-occurring diseases. Antiphospholipid syndrome, heritable connective tissue vasculopathy, and inflammatory endothelial vulnerability are among the candidate mechanisms; none has been confirmed. The more consistent explanation for the two strokes, based on normal day-to-day clotting function, is that chronic systemic inflammation produced transient localized endothelial vulnerability at the time of each event rather than a standing hypercoagulable tendency.

This hypothesis has never been formally evaluated. The purpose of neurology consultation is to determine whether a unified diagnosis exists and what workup is required to establish or exclude it.

II. The Chronological Picture

Pre-2000

Paternal family: multiple siblings with palmar erythema; one brother with RA; one brother with recurring verbal and motor tic disorder; brothers raised in petrochemical refinery environment in East Texas. Father: anosmia to refinery chemicals, indicating lifelong exposure. GSTP1 A/G variant (reduced detoxification capacity) may reflect transgenerational petrochemical exposure effects.

Early Childhood

Continuous secondhand smoke exposure from prenatal period through age 17. Continuous antibiotic exposure infancy through age 7 for recurrent ear infections. Severe enough to produce chronic mastoiditis — structural finding visible on brain imaging from 2016 through 2025. Developmentally significant microbiome disruption during CNS maturation window.

A second independent cognitive baseline predates the 2017 Barrow evaluation. Psychoeducational evaluation by John C. Hollebeek, Ed.D., March 1999, documented verbal functioning at 135 on the WAIS-R, with all MMPI-2 clinical scales within normal range — benign profile with no evidence of psychotic process, delusional thought, or significant anxiety or mood pathology. Two independent evaluations 18 years apart document consistent exceptional cognitive baseline.

~2000

Widespread pain and fatigue diagnosed as fibromyalgia. Fibromyalgia diagnosis likely a placeholder — tender point criteria not clearly met. Retrospective hypothesis: symptoms may represent central sensitization from subclinical CNS small vessel disease, now confirmed as present from at least 2016 and likely earlier. Predates RA diagnosis by approximately 8 years.

Early-to-mid 2000s (pre-2008)

Pregabalin prescribed for fibromyalgia/pain. Produced sudden loss of postural tone without warning — clinically consistent with pregabalin-induced negative myoclonus, a cortical inhibitory phenomenon. Resolved within days of discontinuation. Earliest documented evidence of neurological vulnerability, predating RA diagnosis, all biologic exposure, and the strokes. The posterior circulation architecture subsequently documented on imaging — diminutive vertebrobasilar system dependent on a single fetal vessel — means posterior circulation insufficiency was a structural vulnerability present throughout this period.

Ages 17–30

Significant alcohol use. Ceased at age 30.

Age 17 to present

Tobacco use. Current smoker.

2008

Seropositive RA diagnosed. Methotrexate: reaction began within days of first dose — severe peripheral neuropathy plus unprecedented psychiatric presentation; resolved rapidly and completely after discontinuation; severity substantially exceeded standard low-dose methotrexate expectations.

2008–2018

Consistent pharmacological phenotype across drug classes: complete non-response or amplified neurological reaction, with no middle ground. Pattern reflects constitutionally compromised nervous system responding predictably, not idiosyncratic drug sensitivity. Each neurologically active drug that produced a reaction was an additional CNS insult on an already compromised system.

June 2016 — First Stroke and Baseline Vascular Imaging

Left temporal lobe acute ischemic infarct (1.5 x 2.8 cm); cryptogenic. Extensive embolic source workup negative: carotid duplex (no significant stenosis), transthoracic echo (normal), TEE June 2017 (no cardioembolic substrates, no PFO, bubble study negative), abdominal aortic ultrasound (no aneurysm), serial cardiac follow-up through 2021 — no embolic source identified. MRI same date: small vessel disease already present — “few small scattered foci compatible with minor small vessel ischemic change” — predating the stroke event; this is the earliest documented evidence of small vessel CNS disease. MRA same date (first cerebrovascular imaging ever obtained): diminutive vertebrobasilar system; posterior circulation primarily supplied by ectatic right persistent trigeminal artery; 4mm right cavernous ICA aneurysm; probable 2mm left MCA branch aneurysm. Constitutional vascular architecture fully present at baseline — not acquired during surveillance.

June 2017

Neuropsychological evaluation by Dr. Tricia Merkley, Barrow (full report on file). Above-average baseline confirmed: Full Scale IQ 126 (96th percentile), Verbal Comprehension 132 (98th percentile), Working Memory 131 (98th percentile). Moderate left hand motor impairment documented and flagged as inconsistent with left temporal stroke location. Right hemisphere dysfunction may have been present and progressive before the 2018 stroke — one year before the right insular event. One-day episode of memory disturbance and repetitive thinking noted in this period, attributed to statin side effects at the time; in retrospect, a possible minor vascular event in someone with bilateral progressive small vessel disease between two cryptogenic strokes. The 2017 MRA was focused on the aneurysm and read as normal parenchyma; it was not specifically evaluating for right hemisphere small vessel changes. No follow-up neuropsychological evaluation has been performed since.

Note on cognitive reserve and masking: the exceptional baseline documented in 2017 has masked functional losses from clinical view throughout this history. Compensation at this cognitive level makes deficits invisible against population norms. Strokes that would have produced visible sequelae in most patients produced none that were clinically apparent. A current neuropsychological evaluation compared against the 2017 individual baseline — not population norms — will reveal losses that the clinical picture currently underrepresents. This is the primary reason re-evaluation is urgent rather than merely indicated.

May 2018 — Pre-Stroke Neurological Event

ER visit for headache, CT head normal. Two months before the second stroke; headache in a patient with a known growing intracranial aneurysm warrants noting as a pre-stroke neurological event in the pattern.

July 2018 — Second Stroke

Right insular cortical CVA extending to frontal operculum; cryptogenic — second unexplained stroke. Right insula is primary autonomic integration center; sequelae have never been formally evaluated. Attending cardiologist concluded the stroke appeared potentially related to the growing right ICA aneurysm — a vasculopathic rather than embolic interpretation. CTA same date: right cavernous ICA aneurysm now 6mm — grown from 4mm at 2016 baseline. MRI July 19, 2018: “Chronic small vessel ischemic changes are mild in the juxtacortical and deep white matter of both cerebral hemispheres diffusely” — bilateral distribution is critical: neither the left temporal nor the right insular stroke location explains bilateral white matter changes; this is independent evidence of a diffuse process, not stroke-related damage. MRA July 19, 2018: trigeminal artery confirmed as dominant posterior supply; vertebral arteries and proximal basilar hypoplastic; right ICA aneurysm 5.5mm.

December 2022

Antiphospholipid antibody panel: anticardiolipin IgM 21 (normal <13) — elevated; beta-2 glycoprotein I IgM 63 (normal <33) — markedly elevated; remaining three antibodies negative. Confirmatory testing was never performed. Results were never communicated to Barrow neurology. Open diagnostic question in context of two cryptogenic strokes.

2023–2024 — Aneurysm Treatment and Neurological Events

March 2023: right cavernous ICA aneurysm now approximately 1.2cm — dramatic growth from 6mm in 2018. May 2023: Pipeline embolization, successful. January 2024: ER stroke evaluation — neurological event occurred between the two iron infusions that triggered the 2024 systemic escalation. May 2024: hospitalization for severe balance disorder — unable to walk; stroke evaluation; occurred during documented B12 injection gap. MRI May 2024: “Hyperintense T2 and FLAIR signal greatest in posterior right frontal region, likely due to microvascular disease” — more extensive than 2016, specifically localized adjacent to motor and autonomic pathways.

July 2025 — Structural CNS Findings

MRI with contrast July 30, 2025: there appears to be a very small amount of encephalomalacia in the right insula posteriorly, corresponding to the region of the 2018 infarct — reported as a possible finding rather than definitively confirmed permanent tissue loss. Mild chronic microangiopathy appears slightly increased from the prior MRI July 19, 2018. No pathologic enhancement identified. Persistent right trigeminal artery with proximal ectasia noted, consistent with prior imaging.

October 2025 — MRA Surveillance

MRA head October 3, 2025, ordered by Dr. Ducruet: stable examination. No residual aneurysm at Pipeline stent site. Posterior circulation markedly diminutive, predominantly supplied via persistent right trigeminal artery — unchanged. A previously described outpouching along the dorsal aspect of the persistent trigeminal artery near the brainstem has been characterized on this and the July 2025 MRI as likely representing a small coursing vessel rather than a true aneurysm. Annual surveillance continues at Dr. Ducruet’s clinical discretion given the history of rapid aneurysm growth elsewhere in this vascular system.

Late 2025–Early 2026 — HCQ Vestibular Crisis

Daily hydroxychloroquine initiated mid-to-late December 2025 following months of deliberate resistance to provider recommendation. Acute vestibular crisis developed within days to two weeks of daily dosing — presentation indistinguishable from major stroke, inability to stand, emergency services called. Self-discontinued upon recognizing the connection approximately December 30 or early January 2026. Allergy formally documented January 13, 2026. Residual vestibular and balance damage did not fully resolve. B12 requirement escalated from twice weekly to daily methylcobalamin following this event; daily injections now insufficient.

May 2026 — Active CNS Crisis

Escalation of baseline neurological symptoms crossing threshold for prednisone intervention — conservative marker given PRN-only approach and high threshold for pharmaceutical use. Symptoms included cognitive fog, loss of executive function, and word retrieval failure substantially worse than chronic baseline impairment in these domains; proprioceptive balance disturbance severe enough to require active conscious compensation for walking; anxiety and psychological overwhelm component qualitatively atypical and distinct from usual pattern, suggesting autonomic or limbic involvement beyond the cognitive and motor picture. Partial response to prednisone within hours, consistent with documented pharmacological phenotype of faster-than-expected onset. Residual proprioceptive deficit and word retrieval impairment persisted after inflammatory component partially resolved, consistent with structural substrate underlying the acute episode.

This is not a resolved episode. As of May 2026, the patient remains in active CNS crisis. A high-dose IV nutrient infusion on May 23, 2026 produced transient functional restoration — unable to ambulate before the infusion, ambulating during and after — with effects persisting the following day. The inflammatory floor has been temporarily lowered but is rebuilding. The crisis state is ongoing.

Additional features of the current presentation: word retrieval failure is now a continuous baseline finding rather than episodic — present throughout the day, requiring compensatory strategies including browser search for word retrieval. Processing spikes produce complete cessation of all cognitive function, qualitatively distinct from word retrieval failure and more functionally disabling. RA joint involvement has expanded to additional joints since the 2024 systemic escalation.

A significant shift in symptom expression has occurred in recent months: CNS symptoms have replaced joint symptoms as the primary leading indicator of systemic inflammatory load. The CNS signals — word retrieval failure, processing spikes, cognitive fog, emotional reactivity — are novel enough that they are still registering as information rather than background noise. This provides earlier warning of inflammatory escalation than was previously available, but the window in which these signals remain informative rather than normalized is finite.

August 10, 2026 — NGS Hematology Molecular Profile

Sonora Quest NGS Hematology Molecular Profile, collected 8/10/2026, reported 8/13/2026 (Accession No. 36016670, reviewed by Liwen Lai PhD, DABMGG, FACMG). Full panel of 40+ genes including JAK2, CALR, MPL, ASXL1, and associated fusion and expression targets. Result: 0 relevant biomarkers detected. JAK2 V617F negative. This resolves the longstanding open question of primary versus reactive thrombocytosis in favor of reactive — no clonal molecular driver identified.

August 27, 2026 — Brain MRI

Ordered for memory loss, difficulty swallowing, history of strokes and aneurysm; compared to July 2025 MRI. No acute intracranial findings — no acute infarct on diffusion-weighted imaging, no acute hemorrhage on gradient-echo sequences, ventricles normal in size. NeuroQuant volumetric analysis: hippocampi 37th percentile, whole brain 37th percentile, gray matter 67th percentile, white matter 35th percentile — no abnormal volume loss greater than 2 standard deviations below age-matched norms anywhere measured, including the hippocampi. Mild chronic microvascular white matter changes, reported without interval comparison language. Persistent right trigeminal artery, unchanged. New finding: moderate right and mild left mastoid effusions — fluid, distinct from the chronic mastoiditis structural changes already documented in this history.

The study was performed under a standard acute-stroke protocol (diffusion-weighted, gradient-echo, FLAIR/T2; no MRA or other angiographic sequence). This addresses the memory-loss indication only to the extent of ruling out gross hippocampal atrophy, does not evaluate brainstem or lower cranial nerve structures relevant to the swallowing complaint, and does not assess aneurysm status given the absence of any angiographic sequence — two of the three ordered indications were not substantively addressed by this study.

Location discrepancy, unresolved: this report describes a small area of encephalomalacia in the right parietal lobe. Every prior document in this reference system, including the July 2025 MRI as previously reported, describes the encephalomalacia as located in the right insula, posteriorly, corresponding to the 2018 infarct. The report states comparison was made to the July 2025 MRI but does not state whether this represents the same lesion under different anatomical terminology, a re-read of the same area, or a distinct finding. This needs direct clarification from Dr. Ashby or the reading radiologist — it should not be assumed to be the same finding restated, nor assumed to be a new and different lesion.

The Small Vessel Disease Progression — Summary

Five imaging time points document progressive small vessel CNS disease:

• 2016: present at first stroke imaging, predating the acute event
• 2018: bilateral at time of second stroke — “both cerebral hemispheres diffusely” — independent of either infarct location, confirming diffuse process
• 2024: more extensive, posterior right frontal predominance, adjacent to motor and autonomic pathways
• 2025: mild chronic microangiopathy appears slightly increased from 2018 baseline
• 2026 (August): mild chronic microvascular changes, reported without stated interval comparison to 2025

The small vessel disease predates both strokes, was bilateral at the time of the second stroke, and has continued progressing through and after them. The bilateral 2018 distribution is the strongest imaging evidence that this is a constitutional diffuse process rather than stroke-related focal damage.

The Vestibular and Balance System — Cumulative Insult Pattern

The balance and vestibular system reflects a stepwise permanent worsening that cannot be attributed to any single event. The cumulative sequence:

Constitutional terrain

Genetic vulnerability, early developmental disruption, and years of undiagnosed pernicious anemia producing demyelination across vagal, cerebellar, and vestibular pathways before any treatment began.

Suboptimal B12 management

Years of hydroxocobalamin rather than methylcobalamin, reactive rather than prophylactic dosing, and documented compliance gaps — maintained partial but never full remyelination.

Left temporal lobe ischemic stroke, June 2016

First documented CNS insult in the sequence.

Right insular stroke, 2018

Direct structural damage to primary CNS autonomic and postural integration site, with apparent encephalomalacia on 2025 MRI.

Hydroxychloroquine vestibular crisis, late 2025/early 2026

Acute vestibular damage of sufficient severity to prompt emergency services, with presentation indistinguishable from major stroke and inability to stand; damage did not fully reverse; B12 requirement escalated permanently following this event.

Each insult reduced the baseline. None fully reversed. Current balance function reflects the accumulated total, not any single event. The current functional baseline is permanently lower than pre-2024 and continues to decline. Proprioceptive function now requires increasing conscious effort and compensation for routine ambulation, with intermittent gait abnormality.

The B12 deficiency demyelination and the vascular small vessel disease are distinct contributors to the white matter picture — both are present, both progressing, and standard imaging reads have not distinguished between them. This distinction has clinical implications: vascular small vessel disease is largely irreversible; demyelination from B12 deficiency is at least partially reversible with adequate sustained repletion.

HPA Axis Dysregulation

Absent classic morning stiffness pattern — the typical RA morning gel phenomenon driven by overnight cortisol nadir and inflammatory surge. Absence of this pattern suggests a flattened or blunted diurnal cortisol rhythm rather than normal HPA cycling. Consistent with adrenal insufficiency or HPA axis dysregulation. Low-dose hydrocortisone three times daily initiated — framed as physiologic replacement of a flattened diurnal rhythm rather than pharmacological inflammation suppression.

HPA axis function depends on intact central regulatory capacity including insular and limbic input to the hypothalamus. Documented insular damage and progressive small vessel CNS disease affecting autonomic pathways are consistent with CNS-origin HPA dysregulation as a contributing or primary factor, rather than purely peripheral adrenal insufficiency. This distinction has not been formally evaluated and represents an open diagnostic question.

III. Vascular Findings

Constitutional vascular architecture was fully present at the first available imaging in 2016, with no prior comparisons available. It predates all documented pathology: diminutive vertebrobasilar system, posterior circulation primarily supplied by ectatic right persistent trigeminal artery, right cavernous ICA aneurysm (4mm, grown to approximately 1.2cm by 2023 before Pipeline embolization), probable left MCA branch aneurysm stable across nine years of surveillance.

The right ICA aneurysm grew most rapidly during the period of worst inflammatory activity, consistent with inflammatory mechanisms driving aneurysm expansion. The trigeminal artery ectasia was present at first imaging, suggesting it is constitutional rather than acquired.

Whether the vascular picture reflects a hypercoagulable tendency contributing to the two strokes is unresolved. Based on normal day-to-day clotting function, a primary hypercoagulable state is considered an unlikely primary explanation. The more consistent mechanism is that chronic systemic inflammation produced transient localized endothelial vulnerability at the time of each stroke. Comprehensive cardiac embolic source evaluation including TEE with bubble study found no embolic substrate, consistent with an intrinsic cerebrovascular rather than embolic explanation. JAK2 V617F testing (8/10/2026, NGS Hematology Molecular Profile) is negative, ruling out a clonal myeloproliferative process as a contributor to the thrombocytosis or the vascular picture. Confirmatory antiphospholipid antibody testing has not been performed — the December 2022 draw was never repeated; Medicare declined coverage for confirmatory testing, and the out-of-pocket cost (~$1,500) has been the barrier. Hypercoagulability from an APS mechanism therefore remains genuinely unresolved, not merely unconfirmed pending results.

IV. Genetic Findings (23andMe, partial — fresh analysis pending)

Each result represents one of the possible allele combinations at that locus, with published population-level associations in the research literature. None of these variants were flagged by 23andMe or by Promethease as notable findings. They are recorded here as background genetic context consistent with the constitutional picture, not as evidence supporting any specific mechanism or conclusion. They should not be read as a converging signal toward antiphospholipid syndrome or any other diagnosis.

Not yet assessed: PTPN22 rs2476601 — not genotyped. COL3A1 and other vascular connective tissue genes. Full fresh Promethease analysis pending. Note: Prothrombin G20210A tested December 2022 — negative.

Family genetic data: 23andMe/Ancestry raw data available across approximately 3 generations, 8–10 family members. Promethease analysis planned. Highest priority: brother with tic disorder (paternal line neurological clustering); maternal line members with stroke history. Target variants for comparison: rs7574865, rs4963128, rs5918, rs4880, rs1695, rs1801131, HLA-B27 markers.

V. Family History — Vascular and Autoimmune Pattern

Paternal line: Multiple brothers with palmar erythema; raised in East Texas petrochemical refinery environment. One brother with RA. One brother with recurring verbal and motor tic disorder — uninvestigated and undiagnosed. Father: anosmia to refinery chemicals; palmar erythema pattern. Whether the paternal clustering reflects heritable genetic tendency, transgenerational epigenetic effects of chronic petrochemical exposure, or both is not resolvable from available evidence.

Maternal line: Mother — multiple strokes over final 8–10 years of life; colon cancer. Sisters: celiac disease, Stage IV COPD, RA.

Pattern: Autoimmune and vascular disease clustering across both family lines. Paternal line shows vascular and palmar erythema clustering consistent with heritable constitutional tendency. Maternal line shows stroke burden and autoimmune clustering.

VI. Outstanding Diagnostic Questions

Directly relevant to diagnostic reframing

Antiphospholipid syndrome confirmation

Not performed. Single draw from December 2022 never confirmed and never transmitted to neurology. A confirmatory panel was planned for May 27, 2026 but the draw did not occur; Medicare declined coverage and the out-of-pocket cost (~$1,500) has been the barrier. Confirmatory testing, if obtained, will help distinguish APS as a contributing mechanism from the inflammatory-endothelial explanation currently considered more consistent with the clinical picture.

JAK2 V617F mutation

Negative. NGS Hematology Molecular Profile, collected 8/10/2026, reported 8/13/2026, 0 relevant biomarkers across the full panel (including CALR, MPL, ASXL1). Decades of thrombocytosis is resolved as reactive rather than primary.

Right insular stroke sequelae

Never formally evaluated despite apparent structural damage on 2025 MRI. Right insula involved in autonomic regulation, interoception, pain processing, HPA axis modulation.

Encephalomalacia location discrepancy

The August 27, 2026 MRI describes the encephalomalacia as right parietal lobe; every prior document, including reports of the July 2025 MRI, describes it as right insula, posteriorly. Needs direct clarification: same lesion under different terminology, a re-read, or a distinct finding. This bears directly on the autonomic-regulation argument built around right insular damage throughout this reference system — if the correct location is parietal rather than insular, that argument needs re-examination.

Neuropsychological re-evaluation

No assessment since June 2017, predating the 2018 stroke, the HCQ vestibular crisis, the 2024 dysbiosis escalation, and all subsequent neurological events. The 2017 report documents an exceptional individual baseline. Re-evaluation must be interpreted against that individual baseline, not population norms — deficits invisible against population averages will be measurable against the documented 2017 ceiling.

Important — relevant to fuller diagnostic picture

Distinction between vascular and demyelinating white matter disease

Standard imaging reads have not separated these two contributors. Vascular small vessel disease is largely irreversible; demyelination from B12 deficiency is at least partially reversible with adequate sustained repletion. The distinction has direct clinical implications.

HPA axis dysregulation

Possible CNS-origin etiology given insular and hypothalamic pathway compromise; not yet formally evaluated. Distinguish from peripheral adrenal insufficiency.

HLA-B27 clinical implications

Carrier status documented genetically; never formally assessed for spondyloarthropathy component alongside RA diagnosis.

Mitochondrial workup

Never performed despite consistent multi-system pattern and SOD2 genetic variant.

Lower priority

CNS vasculitis or autoimmune encephalopathy panel

Specific antibody panels never ordered.

Full connective tissue genetic assessment

COL3A1, COL5A1, ACTA2, FBN1 not yet evaluated.

Targeted re-review of 2017 imaging

Specifically for right hemisphere small vessel changes not the focus of the original read.

Trigeminal artery surveillance

A previously described outpouching along the dorsal aspect of the persistent trigeminal artery has been characterized on the most recent MRI and MRA as likely representing a small coursing vessel rather than a true aneurysm. Annual surveillance continues at Dr. Ducruet’s clinical discretion given the history of rapid aneurysm growth elsewhere in this vascular system.

CNS mast cell involvement

Given compromised BBB and resident CNS mast cell population, the systemic mast cell escalation since 2024 may have a neuroinflammatory component that has never been assessed.

VII. Open Questions and Unknowns

• Whether the fibromyalgia symptoms (~2000) represent central sensitization from subclinical CNS small vessel disease — now confirmed as present from at least 2016 — or a separate primary process.
• Whether the right hemisphere dysfunction documented indirectly in 2017 represents a progressive process already underway or a discrete pre-stroke event.
• Whether APS, if confirmed, is primary or secondary to another autoimmune condition.
• Lupus or undifferentiated connective tissue disease has never been formally evaluated as a unifying diagnosis.
• Whether the small vessel disease visible on 2016 imaging was present earlier — and if so, whether it was the substrate for the pregabalin episodes and early fibromyalgia symptoms.
• Whether the white matter changes in the 2024 hospitalization period reflect primarily vascular progression, B12 deficiency demyelination during the injection gap, or both — and to what degree the demyelinating component has recovered with restored B12 repletion.
• Whether the current permanently lowered vestibular and balance baseline has a recoverable demyelinating component that optimized methylcobalamin management could partially address.
• Whether the 1-day cognitive episode in 2017 between strokes represents a third minor vascular event.
• Whether the HPA axis dysregulation reflects CNS-origin regulatory failure from insular and hypothalamic pathway compromise, peripheral adrenal insufficiency, or both.
• Whether the shift from joint-predominant to CNS-predominant symptom expression as the primary systemic inflammation signal represents a permanent change in disease expression or a transient feature of the current crisis period.

VIII. Possible Signals — Undetermined Clinical Significance

The following observations are noted for the record. Each is real and worth flagging for clinical attention. None has been formally evaluated, and the interpretive frameworks suggested are hypothetical. Where a finding might fit into the established analytical picture is noted, but this placement is speculative.

Peripheral vagal dysfunction cluster

Weak gag reflex (documented, St. Joseph’s problem list 2019). Intermittent swallowing dysfunction with occasional aspiration, including choking episodes (observed). Persistent single dry reflexive cough of unclear onset duration (observed). Hoarseness following March 2026 angioedema episode, not fully resolved (observed; laryngeal involvement in that episode is documented). These findings are individually noted but their collective significance is undetermined. If they collectively represent peripheral vagal neuropathy, they would add a peripheral dimension to the central vagal deficit documented in the SetPoint mechanistic reference.

Autonomic afferent signals

Tinnitus previously flare-associated, now continuous (observed progression; tinnitus itself documented in health history). Bladder sensory dysregulation — persistent urinary sensations without infection, pain, or escalation; UA negative May 19, 2026, infectious etiology excluded (observed). If these represent aberrant autonomic afferent signaling, they would be consistent with the broader autonomic dysfunction picture.

Executive function intact, long-term consolidation impaired

In-session reasoning, planning, error-catching, and judgment are sharp and undiminished — observed consistently, including in real time during document review and editing work. Content does not reliably persist once attention moves elsewhere; material reasoned through in one session is often not retrievable afterward, distinct from normal effortful forgetting. Onset and course not yet characterized — unclear whether total or partial, whether modality-specific, and what if anything predicts what is retained versus lost. No formal assessment has evaluated this dissociation. Candidate contributors given the documented CNS history include the 2016 left temporal and 2018 right insular strokes, bilateral progressive small vessel disease across four imaging time points, and the late-2025/early-2026 HCQ vestibular crisis — no single event is established as causative. This is exactly the kind of finding a neuropsychological re-evaluation exists to characterize; none has been performed since June 2017.

Family neurological observations — hypothetical signals

Mother’s fall mechanism: leaning far back to swallow medications, continuing to fall, resulting in hip fracture. Mechanism possibly consistent with sudden postural tone loss rather than simple balance failure — relevant in the context of the patient’s own pregabalin-induced postural tone episodes. Undetermined; could reflect age-related balance decline. Paternal brother’s tic disorder may include a single dry reflexive cough matching the patient’s presentation — pending confirmation from sibling. If confirmed, possible heritable neurological signal in a family line with documented vascular and autoimmune clustering.